Inhibikase Therapeutics Inc(IKT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:56 PM ET (Korea 10/29 05:56)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.44 | Insider Own | 22.35% | Shs Outstand | 132.0M | Perf Week | -2.41% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | -5.72% | Insider Trans | - | Shs Float | 108.3M | Perf Month | -19.8% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.11 | Inst Own | 73.32% | Short Float | 18.11% | Perf Quarter | -28.95% |
| Income | -0.06B | P/S | - | EPS this Y | 11.33% | Inst Trans | 13.03% | Short Ratio | 34.42 | Perf Half Y | -12.9% |
| Sales | 0.00B | P/B | 1.4 | EPS next 5Y | 6.39% | ROA | -48.04% | Short Interest | 19.63M | Perf YTD | -20.98% |
| Book/sh | 1.16 | P/C | 1.42 | EPS past 3/5Y | 51.48% 22% | ROE | -51.96% | 52W High | -37.93% ($2.61) | Perf Year | 10.2% |
| Cash/sh | 1.14 | P/FCF | - | Sales past 3/5Y | - | ROIC | -39.55% | 52W Low | 21.8% ($1.33) | Perf 3Y | 94.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 59.89% | Gross Margin | - | Volatility(W/M) | 6.64% 6.36% | Perf 5Y | -87.02% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.82 | EPS Q/Q | -1.81% | Profit Margin | - | RSI (14) | 34.86 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.82 | Sales Q/Q | - | SMA20 | -8.89% ($1.78) | Beta | 0.9 | Target Price | $5.55 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -23.15% ($2.11) | Rel Volume | 0.67 | Prev Close | $1.57 |
| Employees | 35 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -2.33% - | SMA200 | -16.39% ($1.94) | Avg Volume(3M) | 0.57M | Price | $1.62 |
| IPO | 2020/12/23 | Option/Short | No/Yes | Trades | 2227 | Volume | 382,085 | Change | 3.18% |
💊 Inhibikase Therapeutics (ticker IKT) is a US-based clinical-stage biotech company. It is focused on advancing its lead candidate, IKT-001, through global late-stage clinical trials for the indication of pulmonary arterial hypertension (PAH), and is classified as a dedicated drug development company with no commercialized product revenue to date.
Over the past 1 year, on the lower side
38% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
IKT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +11.3% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 73.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #291 of 594 in the industry
Based on market cap of $226M.
CAMP#289 CAMP4 Therapeutics Corp $229M PER - 
EVMN#290 Evommune Inc $229M PER - IKT#291 Inhibikase Therapeutics Inc $226M PER - 
ELDN#292 Eledon Pharmaceuticals Inc $224M PER - 
SLGL#293 Sol-Gel Technologies Ltd $223M PER - 
FAQ
What kind of company is IKT?
IKT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IKT?
The market cap of IKT is approximately $226M, ranking 3,937 within its sector.
What is the 52-week high and low for IKT?
IKT has recorded a 52-week high of $2.61 and a low of $1.33.
